Efficacy and safety of bedaquiline and delamanid in the treatment of drug-resistant tuberculosis in adults: A systematic review and meta-analysis

基岩 医学 队列 肺结核 内科学 养生 入射(几何) 队列研究 不利影响 置信区间 结核分枝杆菌 病理 物理 光学
作者
Syeda Hoorulain Ahmed,Hoorain Haider,Abdul Moeed,A. H. Mahmood,Nasir Shivani,Syed Hasan Shuja,Javeria Hayat,Bushra Jamil,Razia Fatima
出处
期刊:The Indian journal of tuberculosis [Elsevier BV]
卷期号:71 (1): 79-88 被引量:5
标识
DOI:10.1016/j.ijtb.2023.05.005
摘要

Multi and extensively drug-resistant tuberculosis is a grave cause of global public health concern due to its high mortality and limited treatment options. We conducted this systemic review and meta-analysis to evaluate the efficacy and safety of bedaquiline and delamanid, which have been added to the WHO-recommended regimen for treating drug-resistant tuberculosis. Electronic databases were searched from their inception until December 1st, 2021, for eligible studies assessing the efficacy and safety of bedaquiline and delamanid for treating drug-resistant tuberculosis. Binary outcomes were pooled using a DerSimonian-Laird random-effects model and arcsine transformation and reported on a log scale with a 95% confidence interval (CIs). Twenty-one studies were shortlisted in which bedaquiline, delamanid, and a combination of both were administered in 2477, 937, and 169 patients. Pooled culture conversion at 6 months was 0.801 (p < 0.001), 0.849 (p = 0.059) for bedaquiline and delamanid, respectively, and 0.823 (p = 0.017), concomitantly. In the bedaquiline cohort, the pooled proportion of all-cause mortality at 6 months was reported as 0.074 (p < 0.001), 0.031 (p = 0.372) in the delamanid cohort, and 0.172 in the combined cohort. The incidence of adverse events in the bedaquiline cohort ranged from 11.1% to 95.2%, from 13.2% to 86.2% in the delamanid cohort, and 92.5% in a study in the combined cohort. The incidence of QTC prolongation reported in each cohort is as follows: bedaquiline 0.163 (p < 0.001), delamanid 0.344 (p = 0.272) and combined 0.340 (p < 0.001). Our review establishes the efficacy of delamanid, bedaquiline, and their combined use in treating drug-resistant tuberculosis with reasonable rates of culture conversion, low mortality rates, and safety of co-administration, as seen with their effect on the QTc interval.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
田様应助与非采纳,获得10
1秒前
大模型应助alex采纳,获得10
1秒前
细心荔枝发布了新的文献求助10
1秒前
SciGPT应助假如有贾蓉采纳,获得10
3秒前
未晚完成签到 ,获得积分10
4秒前
5秒前
6秒前
6秒前
6秒前
暖小阳完成签到,获得积分10
7秒前
不是省油的灯完成签到 ,获得积分10
7秒前
mou发布了新的文献求助10
9秒前
柯柯完成签到,获得积分10
10秒前
11秒前
量子星尘发布了新的文献求助10
12秒前
天天快乐应助zjzj采纳,获得10
12秒前
郁离子发布了新的文献求助10
12秒前
13秒前
小草完成签到,获得积分10
13秒前
14秒前
英俊的铭应助955采纳,获得10
14秒前
15秒前
小草发布了新的文献求助10
17秒前
阿叶同学完成签到,获得积分10
17秒前
伯赏孱发布了新的文献求助10
18秒前
www268完成签到 ,获得积分10
18秒前
受伤幻桃发布了新的文献求助10
19秒前
细心荔枝完成签到,获得积分10
19秒前
领导范儿应助一切随风采纳,获得10
20秒前
愤怒的曼荷完成签到,获得积分20
21秒前
乐观思萱发布了新的文献求助10
21秒前
耍酷亦玉应助科研通管家采纳,获得10
21秒前
21秒前
斯文败类应助科研通管家采纳,获得10
21秒前
Ava应助科研通管家采纳,获得10
22秒前
Orange应助科研通管家采纳,获得10
22秒前
22秒前
22秒前
22秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 360
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3971469
求助须知:如何正确求助?哪些是违规求助? 3516210
关于积分的说明 11181332
捐赠科研通 3251376
什么是DOI,文献DOI怎么找? 1795810
邀请新用户注册赠送积分活动 876051
科研通“疑难数据库(出版商)”最低求助积分说明 805245